Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 2
1996 1
1999 7
2000 2
2001 2
2002 4
2004 1
2005 4
2006 3
2007 3
2008 4
2009 1
2010 3
2011 5
2012 5
2013 4
2014 1
2015 1
2016 3
2017 3
2018 3
2019 5
2020 1
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

63 results
Results by year
Filters applied: . Clear all
Page 1
Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial.
Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O, Simmons JH, Padidela R, Namba N, Cheong HI, Pitukcheewanont P, Sochett E, Högler W, Muroya K, Tanaka H, Gottesman GS, Biggin A, Perwad F, Mao M, Chen CY, Skrinar A, San Martin J, Portale AA. Imel EA, et al. Among authors: pitukcheewanont p. Lancet. 2019 Jun 15;393(10189):2416-2427. doi: 10.1016/S0140-6736(19)30654-3. Epub 2019 May 16. Lancet. 2019. PMID: 31104833 Free PMC article. Clinical Trial.
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis.
Insogna KL, Briot K, Imel EA, Kamenický P, Ruppe MD, Portale AA, Weber T, Pitukcheewanont P, Cheong HI, Jan de Beur S, Imanishi Y, Ito N, Lachmann RH, Tanaka H, Perwad F, Zhang L, Chen CY, Theodore-Oklota C, Mealiffe M, San Martin J, Carpenter TO; AXLES 1 Investigators. Insogna KL, et al. Among authors: pitukcheewanont p. J Bone Miner Res. 2018 Aug;33(8):1383-1393. doi: 10.1002/jbmr.3475. Epub 2018 Jun 26. J Bone Miner Res. 2018. PMID: 29947083 Free article. Clinical Trial.
Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period.
Portale AA, Carpenter TO, Brandi ML, Briot K, Cheong HI, Cohen-Solal M, Crowley R, Jan De Beur S, Eastell R, Imanishi Y, Imel EA, Ing S, Ito N, Javaid M, Kamenicky P, Keen R, Kubota T, Lachmann R, Perwad F, Pitukcheewanont P, Ralston SH, Takeuchi Y, Tanaka H, Weber TJ, Yoo HW, Zhang L, Theodore-Oklota C, Mealiffe M, San Martin J, Insogna K. Portale AA, et al. Among authors: pitukcheewanont p. Calcif Tissue Int. 2019 Sep;105(3):271-284. doi: 10.1007/s00223-019-00568-3. Epub 2019 Jun 4. Calcif Tissue Int. 2019. PMID: 31165191 Clinical Trial.
Nutritional hypophosphatemic rickets secondary to Neocate® use.
Akhtar Ali S, Mathalikunnel A, Bhardwaj V, Braskett M, Pitukcheewanont P. Akhtar Ali S, et al. Among authors: pitukcheewanont p. Osteoporos Int. 2019 Sep;30(9):1887-1891. doi: 10.1007/s00198-019-04836-8. Epub 2019 May 29. Osteoporos Int. 2019. PMID: 31143989 Review.
Null mutations of NEUROG3 are associated with delayed-onset diabetes mellitus.
Solorzano-Vargas RS, Bjerknes M, Wang J, Wu SV, Garcia-Careaga MG, Pitukcheewanont P, Cheng H, German MS, Georgia S, Martín MG. Solorzano-Vargas RS, et al. Among authors: pitukcheewanont p. JCI Insight. 2020 Jan 16;5(1):e127657. doi: 10.1172/jci.insight.127657. JCI Insight. 2020. PMID: 31805014 Free PMC article.
Evaluating RANKL and OPG levels in patients with Duchenne muscular dystrophy.
Akhtar Ali S, Kang H, Olney R, Ramos-Platt L, Ryabets-Lienhard A, Cheung C, Georgia S, Pitukcheewanont P. Akhtar Ali S, et al. Among authors: pitukcheewanont p. Osteoporos Int. 2019 Nov;30(11):2283-2288. doi: 10.1007/s00198-019-05077-5. Epub 2019 Aug 7. Osteoporos Int. 2019. PMID: 31392399
Antiobesity effect of diazoxide in obese Zucker rats.
Alemzadeh R, Jacobs W, Pitukcheewanont P. Alemzadeh R, et al. Among authors: pitukcheewanont p. Metabolism. 1996 Mar;45(3):334-41. doi: 10.1016/s0026-0495(96)90287-5. Metabolism. 1996. PMID: 8606640
63 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page